Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares Sold by Knott David M Jr

Knott David M Jr trimmed its holdings in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) by 63.8% in the fourth quarter, HoldingsChannel reports. The firm owned 23,626 shares of the company’s stock after selling 41,702 shares during the period. Knott David M Jr’s holdings in Leap Therapeutics were worth $68,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Prosperity Wealth Management Inc. purchased a new stake in shares of Leap Therapeutics during the fourth quarter worth about $63,000. HighTower Advisors LLC acquired a new stake in Leap Therapeutics during the third quarter worth about $65,000. HB Wealth Management LLC raised its holdings in Leap Therapeutics by 103.2% in the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after buying an additional 26,150 shares during the period. LPL Financial LLC purchased a new position in shares of Leap Therapeutics in the 4th quarter valued at $218,000. Finally, Exome Asset Management LLC acquired a new position in shares of Leap Therapeutics during the third quarter worth about $264,000. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Trading Down 3.6 %

Leap Therapeutics stock opened at $0.31 on Tuesday. Leap Therapeutics, Inc. has a 52 week low of $0.28 and a 52 week high of $4.79. The stock has a market cap of $11.69 million, a P/E ratio of -0.16 and a beta of 0.35. The stock has a 50 day moving average of $0.64 and a 200-day moving average of $2.14.

Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.02. As a group, equities analysts predict that Leap Therapeutics, Inc. will post -1.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Baird R W cut shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th. HC Wainwright reiterated a “neutral” rating on shares of Leap Therapeutics in a report on Thursday, March 27th. Finally, Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $9.00 to $1.25 in a research note on Wednesday, January 29th.

Leap Therapeutics Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.